LAS VEGAS, NV, April 20 /PRNewswire-FirstCall/ - Neuroscience Therapy Corp.
- The number of attendees was 425
- Approximately 75% of attendees were from the USA with the remaining
25% from various countries in Europe, Asia and the Americas
- Specialties included general surgery, thoracic surgery, sports
medicine, obstetrics, orthopedics, homeopathy, integrative medicine,
rehabilitative medicine, family practice, neurosurgery, and a
surprising high number of anesthetists
- P-Stim concept was very well accepted and almost all the attendees
requested a copy of the studies and would like to be notified when
we receive FDA approval
- Approximately 70% of the doctors indicated that they would prefer to
perform auricular electro-acupuncture
- Doctors felt that there is no device similar to P-Stim on the market
- "Innovative and promising concept"
- One doctor said it is difficult to believe that patients could be
pain free for 16-20 weeks after treatment with P-Stim since his
experience has been that his patients are pain free for no more than
2 weeks after treatment with his current methods.
Brief Survey Analysis
- Only surveys completed by U.S. doctors were used and all incomplete
surveys were excluded
- A full analysis of results will be done but the following
interesting results were gathered from the 45 complete surveys
- 58% prefer to use electro-acupuncture on the ear to 31% on the body
(11% said they would continue to use both)
- 48% of participants said a 100% of their patients pay cash for
acupuncture and only 9% of the doctors felt that reimbursement was
an important consideration when deciding on purchasing a new product
- The most important considerations when deciding to purchase a new
product were "efficacy" and "safety". "Ease of use" and "history of
benefit" were somewhat important
- When asked if they would consider P-Stim to be a better approach
than current auricular electro-stimulation methods, 62% said yes and
31% felt that it may be, but wanted to use the product first
- There were no products that would be in direct competition with P-
Stim at the exhibits during the AAMA
FDA Approval for P-Stim
- Full FDA approval was granted on March 30, 2006 to begin marketing
P-Stim in the United States. For further information refer to
Neuroscience Therapy Corp. news releases dated April 19, 2006.
About Neuroscience Therapy Corporation:
Neuroscience Therapy Corporation's operations are located in Southern California. It holds the rights to a new, safe and innovative technology to relieve pain. Its product portfolio consists of two complimentary products: the P-Stim(TM) Electro Stimulation Device and the Multi-Point(TM) Stylus. These products have no known side effects, unlike many pharmaceutical pain relievers. The neurostimulation market is in its infancy and could reach several billion dollars in sales. The Company is working toward being a leader in this market. For more information about Neuroscience Therapy Corp., visit: www.neurosciencetherapy.com.
Legal Notice Regarding Forward Looking Statements
The statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Neuroscience Therapy Corporation
Neuroscience Therapy Corporation